Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Human Resources Officer | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 203,227 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,905 · Balance 203,227 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,905 | $11.15 | $21,240.75 |
DisclosureSEC source: 0001997032-26-000006 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,227 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,100 | $13.31 | $14,635.94 |
DisclosureSEC source: 0001997032-26-000004 · primarydocument.xml · nonDerivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,322 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 58,672 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001997032-26-000004 · primarydocument.xml · derivative · entry 3 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,672 Underlying: Ordinary Shares · 58,672 shares Expires 2036-03-03 F4 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 40,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001997032-26-000004 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,422 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,441 | $13.66 | $19,689.54 |
DisclosureSEC source: 0001997032-26-000003 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,322 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| December 31, 2025 Filed Jan 8, 2026 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1 | $10.99 | $10.99 |
DisclosureSEC source: 0001997032-26-000001 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,763 F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 752 | $12.82 | $9,640.64 |
DisclosureSEC source: 0001997032-25-000004 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,762 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 833 | $15.13 | $12,603.29 |
DisclosureSEC source: 0001562180-25-005189 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,514 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002161 · primarydocument.xml · derivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002161 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,681 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 225 | $20.55 | $4,623.53 |
DisclosureSEC source: 0001562180-25-001914 · primarydocument.xml · nonDerivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,706 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On February 27, 2025, the reporting person sold 225 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,162 | $19.92 | $23,149.25 |
DisclosureSEC source: 0001562180-25-001914 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,931 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 27, 2025, the reporting person sold 1,162 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 225 | $20.55 | $4,623.53 |
DisclosureSEC source: 0001562180-25-001835 · primarydocument.xml · nonDerivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,706 F2 · price: On February 27, 2025, the reporting person sold 225 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,162 | $19.92 | $23,149.25 |
DisclosureSEC source: 0001562180-25-001835 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,931 F1 · price: On February 27, 2025, the reporting person sold 1,162 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 21:34 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 810 | $15.79 | $12,791.68 |
DisclosureSEC source: 0001562180-24-007517 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,093 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.48 USD to $16.01 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 28, 2024 Filed Aug 6, 2024 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,736 | $12.24 | $21,248.64 |
DisclosureSEC source: 0001562180-24-006038 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,903 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 109,443 | $16.30 Strike: $16.30 | $1,783,920.90 |
DisclosureSEC source: 0001562180-24-001987 · primarydocument.xml · derivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,443 Underlying: Ordinary Shares · 109,443 shares Expires 2034-02-26 F2 · derivative.exercise_date: Options to buy 109,443 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 71,574 | $16.30 | $1,166,656.20 |
DisclosureSEC source: 0001562180-24-001987 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,167 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 57,604 | $13.30 Strike: $13.30 | $766,133.20 |
DisclosureSEC source: 0001562180-23-007549 · primarydocument.xml · derivative · entry 2 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,604 Underlying: Ordinary Shares · 57,604 shares Expires 2033-10-30 F2 · derivative.exercise_date: These stock options will vest in equal parts on the first, second, third and fourth anniversary of the grant date. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 37,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-007549 · primarydocument.xml · nonDerivative · entry 1 Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,593 F1 · shares: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.